drugset / Trial / NCT00686270
A Long Term Safety Study of Apricitabine in HIV-infected Patients
NaSingle-groupOpen-labelTreatment
Summary
This study will examine the long term safety of apricitabine in HIV-1 infected patients from studies AVX-301 or AVX-302. Eligible patients are those who have either (a)completed studies AVX-301 or AVX-302; or (b)met the criteria for virological failure/lack of response, and consequently wish to withdraw early from studies AVX-301 or AVX-302.
Timeline
- Start
- 2008-05
- Primary completion
- 2012-05
- Completion
- 2012-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | apricitabine | Small molecule | 800 mg | Oral |
| Subject | apricitabine | Small molecule | 1200 mg | Oral |